Compounds of the formula I:
or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
Understanding the Effects of Ligand Configuration on Protoporphyrinogen IX Oxidase with Rationally Designed 3-(<i>N</i>-Phenyluracil)but-2-enoates
作者:Huang-Ze Yang、Hong-Yun Liu、Sang-Hong Li、Da-Wei Wang、Zhen Xi
DOI:10.1021/acs.jafc.3c08483
日期:2024.4.17
showed that the E isomers of 3-(N-phenyluracil)but-2-enoates displayed improved bioactivity than their corresponding Z isomers. Using molecular simulation studies, we found that the E isomers showed a relatively lower entropy change and could sample more stable binding conformation to the receptor than the Z isomers. Our density functional theory (DFT) calculations showed that the E isomers showed higher
原卟啉原 IX 氧化酶(PPO,EC 1.3.3.4)是绿色除草剂发现的一个有前景的目标。然而,配体构型对 PPO 活性的影响仍知之甚少。在此,我们利用之前开发的活性片段交换和连接(AFEL)方法设计了3-( N-苯基尿嘧啶)but-2-enoates,并合成了一系列具有纳摩尔范围的烟草PPO(NtPPO)抑制效力和前景广阔的新型化合物。除草效力。我们的系统结构-活性关系研究表明,3-( N-苯基尿嘧啶)but-2-烯酸酯的E异构体比其相应的Z异构体表现出更高的生物活性。通过分子模拟研究,我们发现E异构体比Z异构体表现出相对较低的熵变,并且可以采样到与受体更稳定的结合构象。我们的密度泛函理论(DFT)计算表明, E异构体比相应的Z异构体表现出更高的化学反应性和更低的电子化学势。化合物E - Ic成为最佳化合物,其针对 NtPPO 的K i值为 3.0 nM,在 37.5–75 g ai/ha
US8153809B2
申请人:——
公开号:US8153809B2
公开(公告)日:2012-04-10
[EN] DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS<br/>[FR] DIHYDROPYRIDONE URÉES EN TANT QUE MODULATEURS DE P2X7
申请人:HOFFMANN LA ROCHE
公开号:WO2010072599A1
公开(公告)日:2010-07-01
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS
申请人:Brotherton-Pleiss Christine E.
公开号:US20100160388A1
公开(公告)日:2010-06-24
Compounds of the formula I:
or pharmaceutically acceptable salts thereof, wherein m, n, R
1
, R
2
, R
3
, R
4
and R
5
are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.